ZEPOSIA demonstrated a relative reduction in ARR versus Avonex of 48% at one year and 38% at two years (absolute ARR of 0.18 versus 0.35 and 0.17 versus 0.28, respectively). 1,2,3 Treatment with ...
Treatment options for patients with these rare diseases have expanded in recent years, but rheumatologists may have limited experience with systemic vasculitis. Three new guidelines have been released ...
Physician Orders for Life-Sustaining Treatment forms help ensure that resident and surrogate care preferences are honored. Nursing facilities that use Physician Orders for Life-Sustaining Treatment ...
A retrospective analysis suggested that administering rituximab to patients with rheumatoid arthritis complicated by lymphoma, systemic vasculitis, or extra-articular lesions was associated with ...
HIGH POINT, N.C.--(BUSINESS WIRE)--Banner Life Sciences LLC (Banner), a privately held specialty pharmaceutical company, today announced that BAFIERTAM™ (monomethyl fumarate), a novel fumarate for ...
In an open-label, single-group study in which follow-up is ongoing at three South African sites, we investigated treatment with three oral drugs — bedaquiline, pretomanid, and linezolid — that have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results